Don’t Jump to Caplyta or Secuado for Schizophrenia

April 2020

Caplyta (kah-PLY-tah, lumateperone) and Secuado (seh-KWAH-doh, asenapine) will be two new atypical antipsychotics.

There are now over a dozen of these second-generation options...with varying activity at receptors (dopamine, serotonin, etc).

But efficacy seems similar.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Cholesterol Know How Nexletol Stacks Up to Other Non-Statins
NSAIDs Be Ready to Suggest OTC Voltaren Gel Instead of Rx Topical NSAIDs
Practice Be Aware of Changes With Pharmacies Dispensing Insulin Pens
Migraine Think of Meds as Last-Line for Migraine Prophylaxis in Kids
Storage & Disposal Highlight Med Disposal Options for Patients
Neurology & Pain Clear Up Confusion About Low-Dose Naltrexone
Respiratory & Allergy Suggest OTCs for Seasonal Allergies Instead of Montelukast
Antipsychotics Don’t Jump to Caplyta or Secuado for Schizophrenia
Pregnancy Put Macrolide Use During Pregnancy in Perspective
Med Safety Guide Safe Use of Ketamine
New Drugs Save the New Antibiotic Cefiderocol for Salvage Therapy